As wildfires continue to spread across the Los Angeles area, residents with asthma and other respiratory diseases face ...

The U.S. FDA is to temper the alert it put out in November 2023 pointing to a potential risk of CAR T therapies causing de novo malignancies. “There was this issue of possible safety concerns with T ...

Alveolar type 2 (AT2) cells maintain lung health by acting as stem cells and producing pulmonary surfactant. AT2 dysfunction underlies many lung diseases, including interstitial lung disease (ILD), in ...

In the United States, interstitial lung disease affects approximately 650,000 people and causes between 25,000 ... 17 jan 2025 Boro Dropulic to Share Pivotal Insights at Advanced Therapies Week on ...

In a finding with implications for one of the most promising cutting-edge medical treatments, researchers evaluated several measurement techniques commonly used in gene therapy. The study ...

Mu-28ZT2 is under development for the treatment of lung cancer. The therapeutic candidate comprises of T cells genetically modified with viral vector to express chimeric antigen receptor (CAR) ...

A number of vector systems, both viral and nonviral, have been employed for gene delivery to the lung, each of which is associated with particular advantages and disadvantages. At present ...